Side effects of sodium valproate/valproic acid

Reactions ◽  
1983 ◽  
Vol 75 (1) ◽  
pp. 11-12
Keyword(s):  
Valproic Acid ◽  
Side Effects ◽  
Sodium Valproate

scholarly journals Does atorvastatin have augmentative effects with sodium valproate in prevention of migraine with aura attacks? A triple-blind controlled clinical trial

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Reza Ganji ◽  
Nastaran Majdinasab ◽  
Saeed Hesam ◽  
Nazanin Rostami ◽  
Mehdi Sayyah ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Side Effects ◽  
Sodium Valproate ◽  
Migraine With Aura ◽  
Vitamin D3 ◽  
Vascular Function ◽  
Intervention Group ◽  
Pain Severity ◽  
Controlled Clinical Trial ◽  
Prophylactic Regimen

Abstract Background Migraine is a painful and disabling nervous disorder which negatively affects the quality of life. Migraineurs may suffer from a generalized vasomotor dysfunction. Statins improve vasomotor and vascular function, with their pleiotropic effects. We aimed to assess efficacy and safety of adding Atorvastatin to prophylactic regimen in better control of migraine with aura. Methods This triple-blind controlled clinical trial was on 68 patients with migraine with aura. An interval of at least 1 month was given to evaluate vitamin D3 level and eligibility. In patients with vitamin D3 deficiency, the correction with vitamin D supplementation was provided. The patients were randomly assigned to receive atorvastatin 20 mg plus sodium valproate 500 mg or placebo plus sodium valproate 500 mg once a day for 2 months. The patients were evaluated based for the number of attacks and pain severity based on Visual Analogue Scale. Results There was a significant (p = 0.0001) improvement in severity of pain and number of migraine attacks by adding Atorvastin to the prophylactic regimen of patients with migraine with aura. After controlling for variable parameters, the differences between two arms of the study was yet statistically significant (p = 0.0001). A significant number of participants in intervention group were satisfied by their treatment (p = 0.001) with no remarkable side effects (P = 0.315). Conclusions Adding atorvastatin to migraine with aura preventive regimen may help reduce the number of acute attacks and pain severity without causing considerable side effects and led to a better patient satisfaction. Trial registration IRCT20180106038242N1. Registered: 7 February 2018.

scholarly journals Molecular and Therapeutic Potential and Toxicity of Valproic Acid

2010 ◽  
Vol 2010 ◽  
pp. 1-18 ◽  
Author(s):  
Sébastien Chateauvieux ◽  
Franck Morceau ◽  
Mario Dicato ◽  
Marc Diederich
Keyword(s):  
Valproic Acid ◽  
Clinical Trials ◽  
Side Effects ◽  
Histone Deacetylase Inhibitors ◽  
Short Chain Fatty Acid ◽  
Therapeutic Potential ◽  
Mood Stabilizer ◽  
Chain Fatty Acid ◽  
Histone Deacetylation ◽  
Transcription Sites

Valproic acid (VPA), a branched short-chain fatty acid, is widely used as an antiepileptic drug and a mood stabilizer. Antiepileptic properties have been attributed to inhibition of Gamma Amino Butyrate (GABA) transaminobutyrate and of ion channels. VPA was recently classified among the Histone Deacetylase Inhibitors, acting directly at the level of gene transcription by inhibiting histone deacetylation and making transcription sites more accessible. VPA is a widely used drug, particularly for children suffering from epilepsy. Due to the increasing number of clinical trials involving VPA, and interesting results obtained, this molecule will be implicated in an increasing number of therapies. However side effects of VPA are substantially described in the literature whereas they are poorly discussed in articles focusing on its therapeutic use. This paper aims to give an overview of the different clinical-trials involving VPA and its side effects encountered during treatment as well as its molecular properties.

Valproic Acid: A Different View

PEDIATRICS ◽  
1982 ◽  
Vol 70 (2) ◽  
pp. 331-331
Author(s):  
J. Kiffin Penry
Keyword(s):  
Valproic Acid ◽  
Side Effects ◽  
American Academy ◽  
Antiepileptic Drug ◽  
Antiepileptic Drugs ◽  
Published Data ◽  
American Academy Of Pediatrics

The Committee on Drugs of the American Academy of Pediatrics has prepared a statement on the benefits and risks of the antiepileptic drug valproic acid; this statement appears in this issue of Pediatrics (70:316, 1982). This report is extensive and objective in its review of published data on valproic acid, and is of great value to practicing pediatricians for that reason. However, the review fails to place vaiproic acid in perspective with other marketed antiepileptic drugs, which in many instances have equally serious side effects.

scholarly journals MONITORING OF ANTICONVULSANT DRUG SIDE EFFECTS IN OUTPATIENTS WITH EPILEPSY

2018 ◽  
Vol 10 (1) ◽  
pp. 303
Author(s):  
Santi Purna Sari ◽  
Natasha Kurnia Salma S ◽  
Alfina Rianti
Keyword(s):  
Valproic Acid ◽  
Side Effects ◽  
Medical Records ◽  
Side Effect ◽  
Anticonvulsant Drug ◽  
Secondary Data ◽  
Drug Side Effects ◽  
Inclusion Criteria ◽  
Descriptive Data ◽  
Effect Monitoring

Objective: This study aimed to monitor the side effects of carbamazepine, phenytoin, and valproic acid, and combinations of these drugs in adultpatients with epilepsy, to raise awareness of the importance of drug side effect monitoring in hospitals.Methods: In this prospective study, descriptive data were collected from patients who met the inclusion criteria of complete samples. Primary datawere obtained using questionnaires, secondary data were collected from medical records, and analyses were performed using the Naranjo algorithm.Results: Among the 54 included patients, 38 (70.37%) of them experienced drug side effects, and the most frequently observed side effect occurredin 48.15% of study subjects.Conclusion: No correlation was identified between side effects and age (p=0.903) or gender (p=1.000).

scholarly journals HDAC8 Inhibition Reduces Lesional Iba-1+ Cell Infiltration after Spinal Cord Injury without Effects on Functional Recovery

2020 ◽  
Vol 21 (12) ◽  
pp. 4539
Author(s):  
Sven Hendrix ◽  
Selien Sanchez ◽  
Elissia Ventriglia ◽  
Stefanie Lemmens
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Valproic Acid ◽  
Side Effects ◽  
Histone Deacetylase ◽  
Functional Recovery ◽  
Hdac Inhibition ◽  
Beneficial Effects ◽  
Cord Injury ◽  
Classically Activated

Pan-histone deacetylase (HDAC) inhibition with valproic acid (VPA) has beneficial effects after spinal cord injury (SCI), although with side effects. We focused on specific HDAC8 inhibition, because it is known to reduce anti-inflammatory mediators produced by macrophages (Mφ). We hypothesized that HDAC8 inhibition improves functional recovery after SCI by reducing pro-inflammatory classically activated Mφ. Specific HDAC8 inhibition with PCI-34051 reduced the numbers of perilesional Mφ as measured by histological analyses, but did not improve functional recovery (Basso Mouse Scale). We could not reproduce the published improvement of functional recovery described in contusion SCI models using VPA in our T-cut hemisection SCI model. The presence of spared fibers might be the underlying reason for the conflicting data in different SCI models.

Oral valproic acid for epilepsy - long-term experience in therapy and side effects

2008 ◽  
Vol 9 (2) ◽  
pp. 285-292 ◽  
Author(s):  
Thorsten Gerstner ◽  
Nellie Bell ◽  
Stephan König
Keyword(s):  
Valproic Acid ◽  
Side Effects ◽  
Long Term Experience

Liver failure under valproic acid

2011 ◽  
Vol 26 (S2) ◽  
pp. 1282-1282
Author(s):  
C. Schönfeldt-Lecuona ◽  
B.J. Connemann ◽  
R.W. Freudenmann ◽  
C. Hiemke ◽  
M.M. Schmid
Keyword(s):  
Valproic Acid ◽  
Side Effects ◽  
Liver Failure ◽  
Liver Enzymes ◽  
Bipolar Affective Disorder ◽  
Hepatic Function ◽  
Good Tolerability ◽  
Medical Products ◽  
Federal Institute

Valproic acid (VPA, 2-propylvaleric acid) is originally an antiepileptic drug, which has been in use for more than 30 years in over 100 countries. The clinical application of VPA has expanded in the last years. Approval has been granted by the FDA for treatment of migraine and cluster headache in 1996, and for treatment of mania and long-term prophylaxis of bipolar affective disorder in 1995. In ongoing studies, VPA has been reported to inhibit growth of several types of cancer cells; in addition, effects on neurodegeneration, and on virus replication in HIV infection have been demonstrated potentially expanding the application of VPA in the future. Despite a good tolerability of the drug, reports of hepatotoxicty even in patients without risk factors become more frequent. We analysed all cases of VPA induced severe hepatic side effects reported to the german Federal Institute for Pharmaceuticals & Medical Products (BfArM) between 1993 and 2009. A special intention was to detect correlations with present co-medication as a crucial factor in the break-down of hepatic function. As frequent co-medications in VPA-induced hepatic side effects benzodiazepines, and antiepileptics, especially carbamazepine, lamotrigine and topiramate were found. In addition, propofol as a co-medication was found in 4 lethal cases. Different pathomechanisms of VPA hepatotoxicity and a therapeutic approach with carnitine are discussed. Current international guidelines for prevention of VPA-induced liver failure are contrasted. Weekly control of liver enzymes in the first treatment weeks might help to detect VPA-induced hepatic side effects earlier.

Sign in / Sign up

Export Citation Format

Share Document